Commenting on the deal Christophe Berthoux, CEO of Synexus said: “We are delighted to be partnering with LDC. This will give us the firepower to continue expanding our international network and to broaden the number of therapy areas we offer to our pharma and CRO clients.
“We also need to continue to invest in our infrastructure and operations so that we carry on providing clients the best solution delivering thousands of patients and providing excellent quality data.
“We are very grateful to Lyceum. They had the business knowledge and expertise that has helped us transform the company into a professional organisation. The partnership with LDC marks the next phase in our ambitious growth plans.”
Synexus recorded revenues of $63m and profits (EBITDA) of $12m for the financial year ending December 2014, representing a 140 per cent increase in turnover since 2011. Further increases are expected in 2015. Synexus’ contracted order book currently stands at a record $216m an increase of $193m since 2011.
This significant growth has been achieved through a targeted buy-and-build strategy which has included launching new sites and acquiring four businesses since 2007.
Since being taken private in 2007 Synexus has expanded its international network from 13 to 25 dedicated research centres across eight countries. At any one time these centres are involved in more than 200 trials with 14,000 patients. Recent expansion has included new site openings in Hexham in the UK (a pioneering partnership with the NHS), Bochum in Germany, Bucharest in Romania, Poznan in Poland and Sofia in Bulgaria. Synexus also acquired a site near Cape Town in South Africa. This expansion has increased its access to more than 68 million potential patients. In addition it has a network of 25 complementary affiliate sites which further extends Synexus’ reach.
The Synexus model uses its scale to deliver cost advantages and improve speed to market for new compounds. Synexus’ scale also allows it to benefit from its investment in best-in-class quality SOPs, dedicated scientific advisory boards for each therapeutic area and a wide network of KOLs to provide valuable insight to customers. Its specialist tailored enrolment and retention strategies address a key challenge in the global clinical trial industry where almost 90 per cent of all trials undertaken are delayed due to slow patient enrolment resulting in lost sales revenue.
LDC is backing the Synexus management team to realise a clear strategy both through organic growth, using its scale and expertise to continue to take share in what is predominantly a highly fragmented market comprising around 80,000 independent GPs/investigators globally and through the acquisition of a number of potential targets.
The deal was led by LDC Director Ged Gould, who was supported by Investment Directors Simon Braham and Chris Wright. Ged Gould will join the board of Synexus.
Ged Gould, Director and Co-Head of LDC in Manchester, said: “We believe this is a particularly good sector as pharma continues to outsource their development activity. Synexus as the world leader in its field will benefit from this trend as well as the continued growth of the healthcare industry.
"Christophe and the management team have done a fantastic job in building an international network in recent years and we are eager to further support the business break into new markets as it targets opportunities in the US, South America and Asia."
ENDS
Notes to editors:
About Synexus
Synexus® is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus operates a global network of 25 dedicated research centres (DRCs) in eight countries– UK, Germany, Poland, South Africa, Romania, Romania, Bulgaria and Ukraine - focusing on cardiovascular, metabolic (diabetes and obesity), musculo skeletal, respiratory and CNS (dementia and pain) trials mainly in phase III.
About LDC
LDC is the leading private equity company in the UK mid-market. LDC is part of the Lloyds Banking Group and is authorised and regulated by the Financial Conduct Authority. It has completed over 485 investments and has ongoing interests in over 85 businesses in the UK. With a UK regional network, LDC invests up to £100m in MBOs, IBOs and Development Capital transactions in a broad range of sectors including Construction & Property, Financial Services, Healthcare, Industrials, Retail & Consumer, TMT, Travel & Leisure and Support Services. Recent transactions include investments with NEC Group, Waterfall Services, Capital Economics, Eley Group, Adler and Allan, Clifford Thames and Anite Travel.